News for Johnson & Johnson - Google Finance

Is Johnson & Johnson Still a Good Defensive Play?

Fri, 17 May 2013 14:10:37 GMT

Is Johnson & Johnson Still a Good Defensive Play?
Wall St. Cheat Sheet - May 17, 2013

With shares of Johnson & Johnson (NYSE:JNJ) trading at around $87.45, is JNJ an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework: C = Catalyst for the Stock's ...

Johnson & Johnson Rating Reiterated by JPMorgan Chase (JNJ) - The Utah People's Post

Johnson & Johnson Ending Metal-on-Metal Hip Implant Sales (2)

Thu, 16 May 2013 21:00:06 GMT

Johnson & Johnson Ending Metal-on-Metal Hip Implant Sales (2)
Businessweek - May 16, 2013

Johnson & Johnson (JNJ), the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S.

Correction to Thursday's Johnson & Johnson-Metal-on-Metal Hip-Products Story - NASDAQ
Hip implants: Johnson & Johnson's DePuy will stop selling metal-on-metal ... - Mass Device

Johnson & Johnson's Stock Looks Too Healthy - CNBC.com

Wed, 01 May 2013 19:23:03 GMT

Johnson & Johnson's Stock Looks Too Healthy - CNBC.com
CNBC.com - May 1, 2013

While I have always liked health-care giant Johnson & Johnson, it's hard to recommend taking a position at these levels.

Johnson & Johnson to Discontinue Metal-on-Metal Hip Products - NASDAQ.com

Thu, 16 May 2013 22:51:07 GMT

Johnson & Johnson to Discontinue Metal-on-Metal Hip Products - NASDAQ.com
NASDAQ - May 16, 2013

Johnson & Johnson ( JNJ ) said it will discontinue its line of metal-on-metal replacement hips, exiting a product category that became the subject of regulatory scrutiny and thousands of customer lawsuits.

Johnson & Johnson Unveils New Corporate Branding Campaign

Thu, 25 Apr 2013 21:37:44 GMT

Johnson & Johnson Unveils New Corporate Branding Campaign
Forbes - Apr 25, 2013

So ends the new TV spot from TBWA LA for Johnson & Johnson, advertising not the company's baby shampoo or Band-Aids, per se, but the company itself.

Johnson & Johnson to introducing corporate branding campaign to burnish image - Economic Times
J&J launches first corporate brand campaign - Marketing Week

Trying to Burnish Its Image, J.&J. Turns to Emotions

Thu, 25 Apr 2013 00:18:11 GMT

Trying to Burnish Its Image, J.&J. Turns to Emotions
New York Times - Apr 25, 2013

FOR the corporate overseers at Johnson & Johnson, the last few years have been a challenge. Enlarge This Image. A scene from a commercial for Johnson & Johnson's campaign called For All You Love, its first global corporate branding campaign in 10 ...

Shareholders blast Johnson & Johnson management

Thu, 25 Apr 2013 20:26:40 GMT

Shareholders blast Johnson & Johnson management
CBS News - Apr 25, 2013

NEW YORK Several Johnson & Johnson (JNJ) shareholders took the health care giant to task during its annual meeting, citing repeated product recalls, ethical lapses and excessive executive pay.

The Procter & Gamble Company (PG), Johnson & Johnson (JNJ): Billionaire Bill ...

Thu, 16 May 2013 17:39:31 GMT

The Procter & Gamble Company (PG), Johnson & Johnson (JNJ): Billionaire Bill ...
Insider Monkey (blog) - May 16, 2013

Two of The Procter & Gamble Company (NYSE:PG)'s top competitors include Johnson & Johnson (NYSE:JNJ) and Colgate-Palmolive Company (NYSE:CL).

Ex-Johnson & Johnson employee files suit citing discrimination over age and ...

Mon, 06 May 2013 22:47:58 GMT

Ex-Johnson & Johnson employee files suit citing discrimination over age and ...
NJ.com - May 6, 2013

Santos, who worked for Johnson & Johnson and its predecessor company for 14 ½ years, has “a rare and incurable blood disorder” called systemic amyloidosis, the complaint states.

Johnson & Johnson Unit Gets Priority Revenue for Simeprevir NDA

Mon, 13 May 2013 13:01:12 GMT

Johnson & Johnson Unit Gets Priority Revenue for Simeprevir NDA
Fox Business - May 13, 2013

Johnson & Johnson (JNJ) unit Janssen Research and Development LLC said the U.S. Food and Drug Administration has granted priority review to its new drug application for simeprevir, its investigational treatment of genotype 1 chronic hepatitis C in ...

Racing Toward the Next Hepatitis C Drug Approval - Motley Fool
Janssen's experimental drug for hepatitis C gets FDA fast track - The Star-Ledger - NJ.com